Omega-3 Fatty Acids and Airway Inflammation

A real mechanism in inflammatory resolution, a mixed respiratory evidence base, and a popular talking point that does not hold up well.

Resolution rather than suppression

The interesting part of omega-3 biology is not simply that it is anti-inflammatory. It is that EPA and DHA are precursors to a class of compounds — resolvins, protectins and maresins, collectively specialised pro-resolving mediators — that actively terminate an inflammatory response.

This is mechanistically distinct from blocking inflammation. Inflammation is a necessary process; the problem in chronic disease is often that it fails to resolve properly. Supporting resolution is conceptually different from suppressing initiation, and it is a genuinely interesting line of research.

EPA and DHA also compete with arachidonic acid for the enzymes producing eicosanoids, shifting the balance toward less inflammatory mediator profiles.

The respiratory evidence, honestly

Weaker and more mixed than the cardiovascular evidence, and this deserves stating clearly.

Exercise-induced bronchoconstriction has the most encouraging data, with several small trials suggesting benefit. Sample sizes are modest.

Asthma results have been inconsistent across trials, with meta-analyses generally not supporting a clear clinical benefit in adults.

COPD evidence is limited.

Early-life exposure is more interesting — some trials of maternal supplementation during pregnancy have suggested reduced wheeze or asthma incidence in offspring, which is a different question from treating established disease.

The overall picture: plausible mechanism, encouraging in specific niches, not established as a respiratory intervention.

Where the evidence is stronger

Cardiovascular, which is relevant given that oxygen delivery is half the equation.

High-dose purified EPA has been examined in cardiovascular outcome trials with results that shifted clinical guidance. Effects on triglycerides are well established. Blood pressure effects are modest but real.

This matters for anyone thinking about oxygen transport as a system rather than only about airways.

The ratio argument, examined

A very common claim: modern diets have an omega-6 to omega-3 ratio of 15:1 or 20:1 against an ancestral 4:1, and this drives chronic inflammation.

The claim is weaker than its popularity suggests. Absolute omega-3 intake appears to matter more than the ratio. Linoleic acid, the main dietary omega-6, has not been convincingly shown to be pro-inflammatory in humans at typical intakes, and observational data on linoleic acid and cardiovascular outcomes has generally been favourable rather than harmful.

The practical implication: increase omega-3 intake rather than obsessing over eliminating omega-6. Reducing seed oil intake to improve a ratio is a considerably weaker intervention than eating more oily fish.

Sources and practicalities

• Oily fish is the best source — salmon, mackerel, sardines, herring, anchovies. Two portions weekly is the common recommendation.
• Algal oil is the vegan source providing EPA and DHA directly.
• Plant ALA from flax, chia and walnuts converts to EPA and DHA very inefficiently in humans — single-digit percentages for EPA and lower for DHA. It is not equivalent.
• Take with a meal containing fat for absorption.
• Oxidation is a real quality issue. Rancid fish oil is common and counterproductive. If capsules smell strongly rancid, discard them. Store in a cool dark place or the fridge.

Cautions

• Anticoagulants and antiplatelets. Omega-3s have mild antiplatelet activity; additive with warfarin, DOACs, clopidogrel or aspirin.
• Surgery. Often advised to stop one to two weeks before.
• Atrial fibrillation. Some trials of high-dose omega-3 have reported increased AF incidence — worth knowing and discussing if relevant.
• Fish allergy. Algal oil is the alternative.